CF53 |
رقم الكتالوجGC33028 |
CF53 هو مثبط فعال للغاية وانتقائي وفعال عن طريق الفم لبروتين BET ، مع Ki <1 نانومتر ، Kd 2.2 نانومتر و IC50 من 2 نانومتر لـ BRD4 BD1يرتبط CF53 بمجالات BD1 و BD2 لبروتينات BRD2 و BRD3 و BRD4 و BRDT BET ذات التقارب العالي ، وهي انتقائية للغاية على البروتينات المحتوية على برومودومين غير BETيُظهر CF53 نشاطًا قويًا مضادًا للورم في كل من المختبر والحي
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1808160-52-2
Sample solution is provided at 25 µL, 10mM.
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with a Ki of <1 nM, Kd of 2.2 nM and an IC50 of 2 nM for BRD4 BD1. CF53 binds to both the BD1 and BD2 domains of BRD2, BRD3, BRD4, and BRDT BET proteins with high affinities, very selective over non-BET bromodomain-containing proteins. CF53 shows potent anti-tumor activity both in vitro and in vivo[1].
CF53 (Compound 28) binds to both the BD1 and BD2 domains of BRD2, BRD3, BRD4, and BRDT BET proteins with high affinities, Kds are 1.1 nM (BRD2 BD1), 0.6 nM (BRD2 BD2), 0.52 nM (BRD3 BD1), 0.49 nM (BRD3 BD2), 0.8 nM (BRD4 BD2), 2 nM (BRDT BD1), 2.1 nM (BRDT BD2), 47 nM (CREBBP), 570 nM (CECR2), 110 nM (EP300), respectively[1].CF53 exhibits IC50s of 7, 85 nM against MOLM-13 acute leukemia and MDA-MB-231 breast cancer cell lines, respectively[1].
CF53 (25, 50 mg/kg, p.o.) exhibits potent anti-tumor activity both in MDA-MB-231 xenograft tumor model and in RS4;11 model in mice[1].
[1]. Zhao Y, et al. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. J Med Chem. 2018 Jul 26;61(14):6110-6120.
Average Rating: 5
(Based on Reviews and 7 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *